MedTrace Logo

Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial

NCT02219880 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2018-10-15

No results posted yet for this study

Summary

The use of Kava in Generalised Anxiety Disorder: an 18-week double-blind, randomised, placebo-controlled study.

Conditions

  • Generalized Anxiety Disorder

Interventions

DIETARY_SUPPLEMENT

Kava (240mg of kavalactones per day)

Kava 60 milligrams per tablet = 240mg of kavalactones per day

DIETARY_SUPPLEMENT

Placebo

Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.

Sponsors & Collaborators

  • Swinburne University of Technology

    collaborator OTHER

  • The University of Queensland

    collaborator OTHER

  • University of Melbourne

    lead OTHER

Principal Investigators

  • Jerome Sarris, PhD · The University of Melbourne and The Melbourne Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-13
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02219880 on ClinicalTrials.gov